P1, N=47, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027

4 days ago

Trial completion date • Trial primary completion date

Opdivo (nivolumab) • Rituxan (rituximab) • lenalidomide • methotrexate • Truxima (rituximab-abbs) • ABP 206 (nivolumab biosimilar) • Mabtas (rituximab biosimilar) • methotrexate IV

Clinical outcomes and MRI-based neurotoxicity assessment of elderly primary CNS lymphoma. (PubMed, J Clin Neurosci)

In elderly PCNSL patients, R-MPV without routine WBRT provides effective disease control while being associated with less structural brain change. CSF IL-10 may represent a potential biomarker of susceptibility to treatment-related brain structural alterations.

6 days ago

Clinical data • Journal

IL10 (Interleukin 10)

methotrexate • methotrexate IV

13d

Unusual Ampullary Presentation of Pediatric Burkitt Lymphoma: Case Report and Literature Review. (PubMed, Clin Med Insights Case Rep)

Given persistent cholestasis and bleeding risk, the patient underwent Roux-en-Y choledochojejunostomy for biliary decompression, followed by initiation of rituximab-cyclophosphamide-vincristine-doxorubicin-high-dose methotrexate/rituximab-ifosfamide-etoposide-high-dose cytarabine (R-CODOX-M/R-IVAC) with central nervous system prophylaxis...Ampullary BL should be considered in pediatric patients with obstructive jaundice and upper gastrointestinal bleeding. Surgical biliary decompression can stabilize cholestasis and facilitate timely multi-agent chemotherapy.

13 days ago

Journal

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • MME (Membrane Metalloendopeptidase)

Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • methotrexate IV

14d

Successful Use of Epcoritamab in Refractory Diffuse Large B-Cell Lymphoma with Central Nervous System Involvement: A Case Report. (PubMed, Case Rep Oncol)

However, epcoritamab induced a rapid systemic response along with partial neurological improvement. This case highlights the potential role of bispecific antibody therapy in refractory DLBCL with CNS involvement, an area of significant unmet clinical need.

14 days ago

Journal

CD20 (Membrane Spanning 4-Domains A1)

Epkinly (epcoritamab-bysp) • methotrexate IV

18d

IELSG32: Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (clinicaltrials.gov)

P2, N=227, Completed, International Extranodal Lymphoma Study Group (IELSG) | N=126 --> 227

18 days ago

Enrollment change

Rituxan (rituximab) • cytarabine • carmustine • thiotepa • methotrexate IV

19d

Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (clinicaltrials.gov)

P3, N=200, Recruiting, Children's Cancer Group, China | Trial primary completion date: Dec 2025 --> Dec 2026

19 days ago

Trial primary completion date

cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • prednisone • daunorubicin • mercaptopurine • methotrexate IV • vindesine

20d

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov)

P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jan 2027 --> Jul 2027

20 days ago

Trial completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HER-2 positive • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive

methotrexate IV

20d

OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma (clinicaltrials.gov)

P3, N=331, Active, not recruiting, Klinikum Stuttgart | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2028 --> Jun 2028

20 days ago

Enrollment closed • Trial primary completion date

Rituxan (rituximab) • cytarabine • methotrexate IV

26d

NCI-2019-03188: Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)

P2, N=120, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2028 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2027

26 days ago

Trial completion date • Trial primary completion date

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)

cyclophosphamide • sirolimus • fludarabine IV • thiotepa • busulfan • cyclosporin A microemulsion • methotrexate IV

29d

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) (clinicaltrials.gov)

P2, N=40, Completed, Fred Hutchinson Cancer Center | Active, not recruiting --> Completed

29 days ago

Trial completion

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • GATA2 (GATA Binding Protein 2) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)

LDH elevation

methotrexate • fludarabine IV • busulfan • Grafapex (treosulfan) • methotrexate IV

Association of MTHFR gene polymorphisms with methotrexate metabolism in children with acute lymphoblastic leukemia (PubMed, Zhongguo Dang Dai Er Ke Za Zhi)

Serum MTX concentration serves as an objective marker of MTX-related toxicity. Under adequate rescue therapy and concentration monitoring, a single MTHFR polymorphism appears insufficient to guide dose adjustment. A combined strategy is recommended, with concentration monitoring as the primary approach and genetic factors as an adjunct.

1 month ago

Journal

MTHFR (Methylenetetrahydrofolate Reductase)

methotrexate • methotrexate IV

Olverembatinib and high-dose methotrexate in acute lymphoblastic leukemia: delayed methotrexate clearance and increased nephrotoxicity. (PubMed, Leuk Lymphoma)

Flumatinib likewise lowered MTX clearance and raised ≥ grade 2 nephrotoxicity to 29.4%, yet neither effect reached statistical significance. Temporary withdrawal of olverembatinib before HD-MTX infusion may prevent MTX-related nephrotoxicity.

1 month ago

Journal

ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)

methotrexate • Nailike (olverembatinib) • Hansoh Xinfu (flumatinib) • methotrexate IV